Ellen (55 years old) has been diagnosed with breast cancer. It is her second time with active cancer, and she has got metastasis in pelvic. Among other drugs she is treated with capecitabine for her cancer. After starting capecitabine Ellen has developed problems feeling her feet and hands, diarrhea, nausea, vomiting and fatigue.
The fluoropyrimidines (capeitabine) are inactivated by hepatic dihydro-pyrimidine dehydrogenase (DPYD). A polymorphism in the fluoropyri-midine-metabolizing enzyme DPYD (Dihydropyrimidine Dehydrogenase ) is strongly associated with severe and life-threatening toxicity.
Most medications including cancer medication exhibit a wide inter-individual variability in their efficacy. A large part of this variability is due to inherited differences in genes. Some of these changes can be found using a pharmacogenomic test as you can see in the study below.
The Personal Medicine Profile is exactly such a pharmacogenomic test and can be used as a Decision Support Tool for Healthcare Personnel and patients to help them predict which medical treatment will benefit the patient -> helping to find the right medication, in the right dose to the right patient.
The right diagnosis is still to be made by the Doctor. Please, do not change any medication without consulting a Doctor.